

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Not for submission under 37 CFR 1.99)

| | |
|------------------------|--------------------|
| Application Number | 10/547,843 |
| Filing Date | September 6, 2005 |
| First Named Inventor | Takashi HORIGUCHI |
| Art Unit | 1649 |
| Examiner Name | CHERNYSHEV, OLGA N |
| Attorney Docket Number | Q101074 |

U.S. PATENTS

| Examiner Initials* | Cite No | Patent Number | Kind Code ¹ | Issue Date | Name of Patentee or Applicant of cited Document | Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear |
|--------------------|---------|---------------|------------------------|------------|---|---|
| | | | | | | |

U.S. PATENT APPLICATION PUBLICATIONS

| Examiner Initials* | Cite No | Publication Number | Kind Code ¹ | Publication Date | Name of Patentee or Applicant of cited Document | Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear |
|--------------------|---------|--------------------|------------------------|------------------|---|---|
| | | | | | | |

FOREIGN PATENT DOCUMENTS

| Examiner Initials* | Cite No | Foreign Document Number ² | Country Code ² | Kind Code ⁴ | Publication Date | Name of Patentee or Applicant of cited Document | Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear | T ⁵ |
|--------------------|---------|--------------------------------------|---------------------------|------------------------|------------------|---|---|----------------|
| | | | | | | | | |

NON-PATENT LITERATURE DOCUMENTS

| Examiner Initials* | Cite No | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city, and/or country where published. | T ⁵ |
|--------------------|---------|--|----------------|
| | | Peter SEUBERT et al., "Isolation and quantification of soluble Alzheimer's β -peptide from biological fluids", <i>Nature</i> , 1992, 359: 325-327. | N |
| | | Eric R. SIEMERS, MD. et al., "Safety, Tolerability, and Effects on Plasma and Cerebrospinal Fluid Amyloid- β After Inhibition of γ -Secretase", <i>Clinical Neuropharmacology</i> , 2007, 30(6): 317-325. | N |
| | | Eric SIEMERS, MD. et al., "Safety, Tolerability, and Changes in Amyloid β Concentrations After Administration of a γ -Secretase Inhibitor in Volunteers", <i>Clin. Neuropharmacol</i> , 2005, 28(3): 128-132. | N |
| | | Adam S. FLEISHER, MD. et al., "Phase 2 Safety Trial Targeting Amyloid β Production with a γ -Secretase Inhibitor in Alzheimer Disease", <i>Arch Neurol</i> , 2008, 65(8): 1031-1038. | N |
| | | M.G. SPILLANTINI et al., "Different configurational states of β -amyloid and their distributions relative to plaques and tangles in Alzheimer disease", <i>Proc. Natl. Acad. Sci. USA</i> , 1990, 87: 3947-3951. | N |

EXAMINER SIGNATURE

| Examiner Signature | /Olga Chernyshev/ | Date Considered | 12/08/2008 |
|--------------------|-------------------|-----------------|------------|
|--------------------|-------------------|-----------------|------------|

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through a citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 See Kind Codes of USPTO Patent Documents at www.USPTO.GOV or MPEP 901.04. 2 Enter office that issued the document, by the two-letter code (WIPO Standard ST.3). 3 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 4 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. 5 Applicant is to place a check mark here if English language translation is attached.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /OC/